Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong(The University of Texas MD Anderson Cancer Center), Steven G. DuBois(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Shivaani Kummar(Stanford University), Anna F. Farago(Massachusetts General Hospital), Catherine M. Albert(Seattle Children's Hospital), Kristoffer Staal Rohrberg(Copenhagen University Hospital), Cornelis M. van Tilburg(German Cancer Research Center), Ramamoorthy Nagasubramanian(Nemours Children's Clinic), Jordan Berlin(Vanderbilt University Medical Center), Noah Federman(University of California, Los Angeles), Leo Mascarenhas(University of Southern California), Birgit Geoerger(Institut Gustave Roussy), Afshin Dowlati(University Hospitals of Cleveland), Alberto S. Pappo(St. Jude Children's Research Hospital), Stefan Bielack(Klinikum Stuttgart), François Doz(Université Paris Cité), Ray McDermott(St. Vincent's University Hospital), Jyoti D. Patel(University of Chicago), Russell J. Schilder(Thomas Jefferson University), Makoto Tahara(National Cancer Center Hospital East), Stefan M. Pfister(University Hospital Heidelberg), Olaf Witt(Hopp Children's Cancer Center Heidelberg), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Erin R. Rudzinski(Seattle Children's Hospital), Shivani Nanda(Bayer (United States)), Barrett H. Childs(Bayer (United States)), Theodore W. Laetsch(The University of Texas Southwestern Medical Center), David M. Hyman(Cornell University), Alexander Drilon(Cornell University)
Cited by 987Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis